← All trials
NCT04735978
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2020
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Feb 3, 2021
- Last posted
- Jun 28, 2021
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Replimune Inc.Lead sponsor
- Replimune Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.